SI-BONE Inc
NASDAQ:SIBN
Net Margin
SI-BONE Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
SI-BONE Inc
NASDAQ:SIBN
|
606.5m USD |
-18%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
223.6B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
181.8B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
150.3B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
139.3B USD |
13%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.2B USD |
13%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
53.2B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.2B USD |
8%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.3B USD |
75%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
260.4B CNY |
33%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
35B USD |
23%
|
SI-BONE Inc
Glance View
SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. The company is headquartered in Santa Clara, California and currently employs 352 full-time employees. The company went IPO on 2018-10-17. The firm is focused on the development of implantable devices used in the surgical treatment of sacro-pelvic anatomy. Its invasive surgical implant system, iFuse, is used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. Its iFuse Implant System includes a series of triangular titanium implants and the instruments developed to enable surgeons to perform the procedure. Its iFuse system, which includes its implants and instruments, is designed to address the shortcomings of alternative treatments, including open surgery, non-surgical management, and screw-based and other minimally invasive stabilization and fusion procedures. Its iFuse-3D design allows the surgeons to fill the implant with ground-up bone before implantation, which accelerates bone through-growth and biological fixation. The company also provides other technologies for its surgeons other than iFuse and iFuse-3D.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on SI-BONE Inc's most recent financial statements, the company has Net Margin of -18.5%.
You don't have any saved screeners yet